Literature DB >> 18794070

Pancreatic cancer stem cells: implications for the treatment of pancreatic cancer.

Diane M Simeone1.   

Abstract

Pancreatic cancer is a highly lethal disease that is usually diagnosed at a late stage for which there are few effective therapies. Emerging evidence has suggested that malignant tumors are quite heterogeneous and that they are composed of a small subset of distinct cancer cells (usually defined by cell surface marker expression) that are responsible for tumor initiation and propagation, termed cancer stem cells. These cells are termed cancer stem cells because, like normal stem cells, they possess the ability to self-renew and make differentiated progeny. Recent studies of human pancreatic cancers have shown a population of pancreatic cancer stem cells that have aberrantly activated developmental signaling pathways, are resistant to standard chemotherapy and radiation, and have up-regulated signaling cascades that are integral for tumor metastasis. An improved understanding of the biological behavior of these cells may lead to more effective therapies to treat pancreatic cancer. In this review, approaches to develop and test therapeutics targeting pancreatic cancer stem cells are discussed.

Entities:  

Mesh:

Year:  2008        PMID: 18794070     DOI: 10.1158/1078-0432.CCR-08-0584

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  63 in total

Review 1.  Molecular mechanism of pancreatic cancer--understanding proliferation, invasion, and metastasis.

Authors:  André L Mihaljevic; Christoph W Michalski; Helmut Friess; Jörg Kleeff
Journal:  Langenbecks Arch Surg       Date:  2010-03-18       Impact factor: 3.445

2.  Permanently blocked stem cells derived from breast cancer cell lines.

Authors:  Gangadharan B Sajithlal; Kristi Rothermund; Fang Zhang; David J Dabbs; Jean J Latimer; Stephen G Grant; Edward V Prochownik
Journal:  Stem Cells       Date:  2010-06       Impact factor: 6.277

Review 3.  ABC transporters as molecular effectors of pancreatic oncogenic pathways: the Hedgehog-GLI model.

Authors:  Marta Santisteban
Journal:  J Gastrointest Cancer       Date:  2010-09

4.  Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival.

Authors:  Berna C Özdemir; Tsvetelina Pentcheva-Hoang; Julienne L Carstens; Xiaofeng Zheng; Chia-Chin Wu; Tyler R Simpson; Hanane Laklai; Hikaru Sugimoto; Christoph Kahlert; Sergey V Novitskiy; Ana De Jesus-Acosta; Padmanee Sharma; Pedram Heidari; Umar Mahmood; Lynda Chin; Harold L Moses; Valerie M Weaver; Anirban Maitra; James P Allison; Valerie S LeBleu; Raghu Kalluri
Journal:  Cancer Cell       Date:  2014-05-22       Impact factor: 31.743

Review 5.  Hyaluronan-CD44 interactions as potential targets for cancer therapy.

Authors:  Suniti Misra; Paraskevi Heldin; Vincent C Hascall; Nikos K Karamanos; Spyros S Skandalis; Roger R Markwald; Shibnath Ghatak
Journal:  FEBS J       Date:  2011-03-25       Impact factor: 5.542

Review 6.  Signaling Networks That Control Cellular Plasticity in Pancreatic Tumorigenesis, Progression, and Metastasis.

Authors:  Howard C Crawford; Marina Pasca di Magliano; Sulagna Banerjee
Journal:  Gastroenterology       Date:  2019-02-01       Impact factor: 22.682

7.  BET bromodomain inhibitors block growth of pancreatic cancer cells in three-dimensional collagen.

Authors:  Vaibhav Sahai; Krishan Kumar; Lawrence M Knab; Christina R Chow; Sania S Raza; David J Bentrem; Kazumi Ebine; Hidayatullah G Munshi
Journal:  Mol Cancer Ther       Date:  2014-05-07       Impact factor: 6.261

Review 8.  Interplay of tumor microenvironment cell types with parenchymal cells in pancreatic cancer development and therapeutic implications.

Authors:  Praveen Guturu; Vijay Shah; Raul Urrutia
Journal:  J Gastrointest Cancer       Date:  2009-06-10

Review 9.  Therapeutic antibodies for the treatment of pancreatic cancer.

Authors:  Patrick Chames; Brigitte Kerfelec; Daniel Baty
Journal:  ScientificWorldJournal       Date:  2010-06-15

10.  MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells.

Authors:  Qing Ji; Xinbao Hao; Min Zhang; Wenhua Tang; Meng Yang; Ling Li; Debing Xiang; Jeffrey T Desano; Guido T Bommer; Daiming Fan; Eric R Fearon; Theodore S Lawrence; Liang Xu
Journal:  PLoS One       Date:  2009-08-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.